Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Maintenance Treatment of Depression in Old Age

Maintenance Treatment of Depression in Old Age ORIGINAL ARTICLE A Randomized, Double-blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Combined With Antidepressant Pharmacotherapy Charles F. Reynolds III, MD; Meryl A. Butters, PhD; Oscar Lopez, MD; Bruce G. Pollock, MD, PhD; Mary Amanda Dew, PhD; Benoit H. Mulsant, MD; Eric J. Lenze, MD; Margo Holm, PhD; Joan C. Rogers, PhD; Sati Mazumdar, PhD; Patricia R. Houck, MSH; Amy Begley, MA; Stewart Anderson, PhD; Jordan F. Karp, MD; Mark D. Miller, MD; Ellen M. Whyte, MD; Jacqueline Stack, MSN; Ariel Gildengers, MD; Katalin Szanto, MD; Salem Bensasi, BA; Daniel I. Kaufer, MD; M. Ilyas Kamboh, PhD; Steven T. DeKosky, MD Context: Cognitive impairment in late-life depression observed (treatment time interaction, F = 2.94; P = .06). 2,137 is a core feature of the illness. The donepezil group was more likely than the placebo group to experience recurrent major depression (35% [95% con- Objective: To test whether donepezil hydrochloride and fidence interval {CI}, 24%-46%] vs 19% [95% CI, 9%- antidepressant therapy is superior to placebo and antidepres- 29%], respectively; log-rank  = 3.97; P = .05; hazard ra- sant therapy in improving cognitive performance and instru- tio = 2.09 [95% CI, 1.00-4.41]). Post hoc subgroup analyses mental http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Psychiatry American Medical Association

Loading next page...
 
/lp/american-medical-association/maintenance-treatment-of-depression-in-old-age-ZcKxoFR6bF
Publisher
American Medical Association
Copyright
Copyright 2011 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-622X
eISSN
2168-6238
DOI
10.1001/archgenpsychiatry.2010.184
pmid
21199965
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE A Randomized, Double-blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Combined With Antidepressant Pharmacotherapy Charles F. Reynolds III, MD; Meryl A. Butters, PhD; Oscar Lopez, MD; Bruce G. Pollock, MD, PhD; Mary Amanda Dew, PhD; Benoit H. Mulsant, MD; Eric J. Lenze, MD; Margo Holm, PhD; Joan C. Rogers, PhD; Sati Mazumdar, PhD; Patricia R. Houck, MSH; Amy Begley, MA; Stewart Anderson, PhD; Jordan F. Karp, MD; Mark D. Miller, MD; Ellen M. Whyte, MD; Jacqueline Stack, MSN; Ariel Gildengers, MD; Katalin Szanto, MD; Salem Bensasi, BA; Daniel I. Kaufer, MD; M. Ilyas Kamboh, PhD; Steven T. DeKosky, MD Context: Cognitive impairment in late-life depression observed (treatment time interaction, F = 2.94; P = .06). 2,137 is a core feature of the illness. The donepezil group was more likely than the placebo group to experience recurrent major depression (35% [95% con- Objective: To test whether donepezil hydrochloride and fidence interval {CI}, 24%-46%] vs 19% [95% CI, 9%- antidepressant therapy is superior to placebo and antidepres- 29%], respectively; log-rank  = 3.97; P = .05; hazard ra- sant therapy in improving cognitive performance and instru- tio = 2.09 [95% CI, 1.00-4.41]). Post hoc subgroup analyses mental

Journal

JAMA PsychiatryAmerican Medical Association

Published: Jan 1, 2011

References